Kaitlyn D’Onofrio

DocwireNews

A study evaluated the relationship between utilization management policy and uptake of hypofractionated radiotherapy in patients with early-stage <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/people-with-indigenous-american-ancestry-have-a-higher-risk-of-developing-her2-positive-breast-cancer/">breast cancer</a>.&ldquo;Breast cancer accounts for the largest portion of cancer-related spending in the United States. Although hypofractionated radiotherapy after breast-conserving surgery is a cost-effective and convenient treatment strategy for patients with early-stage breast cancer, less than 40% of eligible women received hypofractionated radiotherapy in 2013,&rdquo; observed the study authors.The researchers retrospectively analyzed administrative claims data from Jan. 1, 2012, through June 1, 2018, of women aged &ge;18 years with <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/patient-simulation-project-improves-quality-of-care-for-lung-and-breast-cancer-patients/">early-stage breast cancer</a> who were eligible for hypofractionated radiotherapy based on 2011 American Society for Radiation Oncology guidelines. Women were continuously enrolled in one of 14 geographically diverse commercial health plans. Exclusion criteria included receipt of mastectomy, brachytherapy, or less than 11 or more than 40 external beam fractions of radiotherapy. The use of hypofractionated radiotherapy in patients with fully insured and Medicare Advantage plans was encouraged by a utilization management policy, which dictated that extended-course radiotherapy claims would not be reimbursed for fully insured women eligible for hypofractionated radiotherapy. A comparison group was comprised of women in self-insured or Medicare supplemental (self-insured) plans. The main outcome measure was hypofractionated radiotherapy use, with cost serving as a secondary outcome.Data on 10,540 eligible women were identified, of whom about a third (n=3,619; 34.3%) were subject to the policy because they were enrolled in fully insured plans. Mean age at the start of radiotherapy was 63.8 years in the fully insured group and 65.0 years in the self-insured group. No significant differences were observed in mean baseline Charlson Comorbidity Index score (3.0 vs. 3.2, respectively) or practice setting (outpatient hospital setting, 82.4% vs. 80.9%, respectively). Among fully insured patients subject to the policy, it was associated with greater use of hypofractionated radiotherapy (adjusted percentage point difference-in-difference, 4.2%; 95% confidence interval (CI), 0.0% to 8.4%; P=0.05) as well as a nonsignificant decrease in radiotherapy-associated expenditures (&minus;$2,275 relative to self-insured patients; P=0.09). Upon spillover analysis the researchers observed that hypofractionated radiotherapy increased significantly more among self-insured patients who were indirectly exposed to the policy (adjusted percentage point difference-in-difference, 8.5%; 95% CI, 3.6% to 13.5%; P&lt;0.001) versus those not exposed.The study was published in <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2764542">JAMA Oncology</a>.&ldquo;This study suggests that a payer&rsquo;s utilization management policy was associated with direct and spillover increases in the use of hypofractionated radiotherapy, even after accounting for a long-term secular trend in the uptake of hypofractionated radiotherapy in the control groups,&rdquo; summarized the researchers. &ldquo;Utilization management may promote evidence-based cancer care.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Is Utilization Management Policy Correlated with Uptake of Hypofractionated Radiotherapy in Early-Stage Breast Cancer?

Breast Cancer News

A study evaluated the relationship between utilization management policy and uptake of hypofractionated radiotherapy in patients with early-stage breast cancer. ...

Is Utilization Management Policy Correlated with Uptake of Hypofractionated Radiotherapy in

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe